SARS-COV-2 pandemic: establishing three risk levels for 19 Italian regions and two autonomous provinces

Eur J Hosp Pharm. 2022 May;29(3):e3. doi: 10.1136/ejhpharm-2021-002692. Epub 2021 Feb 8.

¹ HTA Unit, Regione Toscana, Firenze, Toscana, Italy andrea.messori.it@gmail.com.
² Hospital Pharmacy, Azienda Sanitaria di Firenze, Firenze, Toscana, Italy.
³ Scientific Direction, SIFaCT, Milan, Italy.
⁴ Hospital Pharmacy, Azienda ULSS 5 Polesana, Rovigo, Veneto, Italy.
⁵ Hospital Pharmacy, Centro di Riferimento Oncologico, Aviano, Italy.
⁶ HTA Unit, Regione Toscana, Firenze, Toscana, Italy.
⁷ Hospital Pharmacy, Azienda Sanitaria Universitaria Giuliano Isontina, Presidio Ospedale Maggiore, Trieste, Italy.
⁸ Pharmaceutical Sciences, Universita degli Studi di Padova, Padova, Veneto, Italy.
⁹ Department of Pharmaceutical Sciences, Universita degli Studi di Padova, Padova, Veneto, Italy.
¹⁰ Pharmacy, Azienda Sanitaria Locale Salerno, Salerno, Campania, Italy.
¹¹ Hospital Pharmacy, Bolzano Hospital, Bolzano, Italy.
¹² Presidency, SIFaCT President, Italian Society for Clinical Pharmacy and Therapy, Milano, Milano, Italy.
¹³ HTA Unit, Regional Health Service, Firenze, Italy.

No abstract available

Keywords: COVID-19; health care economics and organisations; health services administration; organisation and administration; public health.

Publication types